Skip to main content

Table 1 Baseline demographic and clinical profiles

From: Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study

 

Completed ( n= 22)

Withdrawn ( n= 7)

P a

Sex (male/female)

10/12

3/4

0.59

Age, year

52.1 (14.4)

46.5 (14.1)

0.49

Clinical subtype

  

0.49

 Paranoid

18

7

 

 Disorganized

1

0

 

 Catatonic

1

0

 

 Residual

2

0

 

Reason for switching

  

0.60

 Treatment resistant

13

3

 

 Treatment intolerant

5

3

 

 Resistant and intolerant

4

1

 

Education, year

   

 Subject

12.9 (1.8)

13.0 (1.0)

0.59

 Father

12.3 (2.6)

10.5 (1.9)

0.28

 Mother

12.0 (2.6)

10.0 (1.7)

0.25

Previous antipsychotics

  

0.13

 Haloperidol

5

3

 

 Risperidone

12

4

 

 Others

5

0

 

Average dose of previous antipsychotics (mg/day)

445.9 (230.6)

409.2 (303.8)

0.63

  1. Values are expressed as the mean (SD) unless otherwise indicated.
  2. aDifferences in two groups with P values calculated by the Wilcoxon test or the χ 2 test (sex, clinical subtype, reason for switching, and previous antipsychotics).